公开(公告)号：US20240269187A1

公开(公告)日：2024-08-15

申请号：US18628251

申请日：2024-04-05

申请人： The General Hospital Corporation d/b/a Massachusetts General Hospital ,  Dana-Farber Cancer Institute, Inc.

发明人： Anne Fletcher ,  Shannon J. Turley ,  Biju Parekkadan

IPC分类号： A61K35/26 ,  A61K35/12 ,  A61K38/18 ,  A61K38/19 ,  A61K38/20 ,  C12N5/077 ,  C12N5/078

CPC分类号： A61K35/26 ,  C12N5/0651 ,  C12N5/0669 ,  A61K2035/122 ,  A61K38/1866 ,  A61K38/19 ,  A61K38/204

摘要： A method for suppressing an immune response is provided. The method involves administration of isolated lymphoid tissue-derived suppressive stromal cells (LSSC) to a subject in need of such treatment in an amount effective to suppress the immune response in the subject. The invention also involves a method to isolate LSSC by digesting lymphoid tissue fragments using a combination of an enzyme mix and agitation and then collecting the LSSC. Pharmaceutical preparations comprising LSSC are also provided.

公开(公告)号：US20240197848A1

公开(公告)日：2024-06-20

申请号：US18588535

申请日：2024-02-27

申请人： Gdanski Uniwersytet Medyczny

发明人： Piotr Trzonkowski ,  Malgorzata Mysliwiec ,  Natalia Marek-Trzonkowska

IPC分类号： A61K39/00 ,  A61K35/17 ,  A61K35/26 ,  C12N5/0783 ,  C12N13/00

CPC分类号： A61K39/0008 ,  A61K35/17 ,  A61K35/26 ,  C12N5/0637 ,  C12N13/00 ,  A61K2039/5158 ,  A61K2039/55 ,  C12N2501/2302 ,  C12N2502/11

摘要： The gist of the invention consists in the therapeutic vaccine for treatment of diabetes type 1 in children, which contains



Treg cells CD3(+)CD4(+)CD25(high)CD127(−). Claimed too is the cell sorter used to produce the vaccine and the method of multiplying Treg cells in vitro.

公开(公告)号：US20180328917A1

公开(公告)日：2018-11-15

申请号：US15776463

申请日：2016-11-14

申请人： OBERON SCIENCES ILAN LTD.

发明人： Yaron ILAN

IPC分类号： G01N33/50 ,  G06F3/01 ,  A61B5/04 ,  A61B5/00 ,  G06F19/26

CPC分类号： G01N33/5091 ,  A61B5/04 ,  A61B5/486 ,  A61K31/00 ,  A61K35/26 ,  G01N2800/52 ,  G06F3/011 ,  G06F19/26 ,  G06F2203/011

摘要： The invention provides methods and systems for the treatment and diagnosis of pathologic disorders by modulating a physiological state of a target biological entity via exposure of the target entity to a single or a plurality of triggered entities and for transferring of information in a non-direct way and as part of virtual reality interactive environment.

公开(公告)号：US20180318322A1

公开(公告)日：2018-11-08

申请号：US15775358

申请日：2016-11-10

申请人： CITY OF HOPE

发明人： Defu ZENG

IPC分类号： A61K31/675 ,  A61K31/7056 ,  C07K16/28 ,  A61K35/17 ,  A61K35/14 ,  A61K35/26 ,  A61K35/28 ,  A61P37/06

CPC分类号： A61K31/675 ,  A01K2207/20 ,  A01K2227/105 ,  A01K2267/0387 ,  A61K31/00 ,  A61K31/7056 ,  A61K35/14 ,  A61K35/17 ,  A61K35/26 ,  A61K35/28 ,  A61P37/06 ,  C07K16/2809

摘要： Disclosed herein are conditioning regimens and methods for inducing MHC- or HLA-mismatched mixed chimerism by conditioning a recipient with radiation-free, low-doses of cyclophosphamide (CY), pentostatin (PT), and anti-thymocyte globulin (ATG) prior to transplantation of donor bone marrow cells. In certain embodiments, the donor bone marrow cells may be CD4+ T-depleted bone marrow cells. The conditioning regimens and methods may also include administering one or more populations of conditioning donor cells selected from donor CD4+ T-depleted spleen cells, donor CD8+ T cells, and donor G-CSF-mobilized peripheral blood mononuclear cells. The conditioning regimen is clinically acceptable and can be used for treating hereditary hematological diseases and autoimmune diseases, as well as for promoting organ transplantation immune tolerance.

公开(公告)号：US20180134795A1

公开(公告)日：2018-05-17

申请号：US15314337

申请日：2015-06-17

申请人： CELLECTIS

发明人： Roman GALETTO

IPC分类号： C07K16/28 ,  C07K14/735 ,  C07K14/705 ,  C12N15/85 ,  A61K35/17

CPC分类号： C07K16/2866 ,  A61K35/17 ,  A61K35/26 ,  A61K39/0011 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/70503 ,  C07K14/70517 ,  C07K14/70535 ,  C07K2319/03 ,  C12N15/85

摘要： The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen CD123. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen CD123. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially leukemia.

公开(公告)号：US20170335331A1

公开(公告)日：2017-11-23

申请号：US15516240

申请日：2015-10-15

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： Yangbing Zhao ,  Jiangtao Ren ,  Xiaojun Liu ,  Carl H. June

IPC分类号： C12N15/113 ,  A61K35/26 ,  A61K39/00 ,  C12N15/85 ,  A61K35/17 ,  C12N2310/20

CPC分类号： C12N15/1138 ,  A61K35/17 ,  A61K35/26 ,  A61K39/0011 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61P35/00 ,  A61P37/06 ,  C12N15/85 ,  C12N2310/10 ,  C12N2310/20 ,  C12N2501/48 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2501/998 ,  C12N2510/00

摘要： The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR α chain, TCR β chain, beta-2 microglobulin, a HLA molecule, CTLA-4, PD1, and FAS and further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.

公开(公告)号：US20170290858A1

公开(公告)日：2017-10-12

申请号：US15516052

申请日：2015-10-15

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： Yangbing ZHAO ,  Jiangtao REN ,  Xiaojun LIU ,  Carl H. JUNE

IPC分类号： A61K35/26 ,  C12N15/113 ,  C12N15/85 ,  A61K39/00

CPC分类号： C12N15/1138 ,  A61K35/17 ,  A61K35/26 ,  A61K39/0011 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61P35/00 ,  A61P37/06 ,  C12N15/85 ,  C12N2310/10 ,  C12N2310/20 ,  C12N2501/48 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2501/998 ,  C12N2510/00

摘要： The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR α chain, TCR β chain, beta-2 microglobulin and FAS further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.

公开(公告)号：US20170007697A1

公开(公告)日：2017-01-12

申请号：US15276327

申请日：2016-09-26

申请人： Children's Hospital of Orange County

发明人： Mustafa Kabeer

IPC分类号： A61K39/39 ,  B02C23/16 ,  B02C19/20 ,  A61K39/09 ,  A61K45/06

CPC分类号： A61K39/39 ,  A61K35/26 ,  A61K35/744 ,  A61K38/19 ,  A61K39/092 ,  A61K45/06 ,  A61K2039/515 ,  A61K2039/5158 ,  A61K2039/52 ,  A61K2039/521 ,  A61K2039/545 ,  A61K2039/55588 ,  A61K2039/575 ,  B02C19/20 ,  B02C23/16 ,  B02C2023/165

摘要： A method of potentiating an immune response against a cancer, non-cancerous tumor or both in a patient is provided. The method includes administering splenocytes harvested from all or a part of a patient's spleen. The splenocytes can be administered in combination with a biological response modifier to potentiate an immune response against a cancer, non-cancerous tumor or both in a patient.

摘要翻译： 提供了增强对癌症，非癌性肿瘤或两者在患者中的免疫应答的方法。 该方法包括施用从患者脾脏的全部或部分收获的脾细胞。 脾细胞可以与生物反应调节剂组合施用，以加强针对癌症，非癌性肿瘤或患者两者的免疫应答。

公开(公告)号：US20160165861A1

公开(公告)日：2016-06-16

申请号：US14965451

申请日：2015-12-10

申请人： Regents of the University of Minnesota

发明人： Bernhard J. HERING ,  Christopher BURLAK

IPC分类号： A01K67/027 ,  C07K16/28 ,  C12N5/071

CPC分类号： A01K67/0275 ,  A01K2217/15 ,  A01K2227/108 ,  A01K2267/025 ,  A61K31/436 ,  A61K31/675 ,  A61K35/12 ,  A61K35/15 ,  A61K35/26 ,  A61K35/28 ,  A61K35/39 ,  A61K39/395 ,  A61K45/06 ,  C07K16/2833 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K2317/76 ,  C07K2319/30 ,  C12N5/0676 ,  C12N5/0677 ,  C12N15/113 ,  C12N2310/10 ,  C12N2310/20 ,  A61K2300/00

摘要： Genetically modified cells, tissues, and organs for treating or preventing diseases are disclosed. Also disclosed are methods of making the genetically modified cells and non-human animals.

摘要翻译： 公开了用于治疗或预防疾病的转基因细胞，组织和器官。 还公开了制备经遗传修饰的细胞和非人动物的方法。

公开(公告)号：US09205111B2

公开(公告)日：2015-12-08

申请号：US10583860

申请日：2004-12-22

申请人： Takashi Nishimura ,  Masaki Yasukawa

发明人： Takashi Nishimura ,  Masaki Yasukawa

IPC分类号： C12N5/00 ,  C12N5/08 ,  C12N15/63 ,  C07H21/04 ,  A01N63/00 ,  A61K39/395 ,  A61K48/00 ,  A61K35/26 ,  A61K39/00 ,  C12N5/0783 ,  C12N15/85 ,  C12N5/16

CPC分类号： A61K35/26 ,  A61K39/0011 ,  A61K39/395 ,  A61K2039/5156 ,  C07H21/04 ,  C12N5/0636 ,  C12N5/16 ,  C12N15/63 ,  C12N15/85

摘要： A novel process for preparing tumor-specific T cells is disclosed. According to the invention, antitumor-active, tumor-specific T cells are prepared by transducing a TCR gene from a tumor-specific CTL into antitumor-active T cells that have been nonspecifically activated, thus enabling tumor-specific cellular immunotherapy to be carried out from even small amounts of blood. MHC class I-restricted, tumor-specific Th cells are obtained by the method, allowing for the production of cells that react with tumor cells expressing an MHC class I molecule and show a helper activity and an antitumor activity.

摘要翻译： 公开了一种制备肿瘤特异性T细胞的新方法。 根据本发明，通过将来自肿瘤特异性CTL的TCR基因转导至非特异性激活的抗肿瘤活性T细胞来制备抗肿瘤活性的肿瘤特异性T细胞，从而能够进行肿瘤特异性细胞免疫治疗 从少量的血液。 通过该方法获得MHC I类限制性肿瘤特异性Th细胞，允许产生与表达MHC I类分子的肿瘤细胞反应并显示辅助活性和抗肿瘤活性的细胞。